|Table of Contents|

Analysis of postoperative recurrence and influencing factors of epithelial ovarian cancer patients with initial cytoreductive surgery

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 02
Page:
307-310
Research Field:
Publishing date:

Info

Title:
Analysis of postoperative recurrence and influencing factors of epithelial ovarian cancer patients with initial cytoreductive surgery
Author(s):
Wang Qiuyu1; Li Xiaoxiang2; Zhu Junyi1
1.Department of Obstetrics and Gynecology,Nanyang Central Hospital,Henan Nanyang 473000,China;2.Nanyang Center for Disease Control and Prevention,Henan Nanyang 473000,China.
Keywords:
epithelial ovarian cancer; cytoreductive surgery; postoperative recurrence; influencing factors
PACS:
R737.31
DOI:
10.3969/j.issn.1672-4992.2019.02.032
Abstract:
Objective:To investigate the postoperative recurrence and influencing factors of epithelial ovarian cancer patients with initial cytoreductive surgery,and to provide an effective theoretical basis for reducing the recurrence of epithelial ovarian cancer patients with initial cytoreductive surgery and improving the patients' quality of life after operation.Methods:The clinical data of 186 patients with epithelial ovarian cancer treated by cytoreductive surgery from January 2008 to December 2012 were retrospectively analyzed.The patients were divided into recurrent group and non recurrent group according to the recurrence of the patients.The difference of the two groups were observed,including age,histological type,chemotherapy methods,neoadjuvant chemotherapy,clinical staging,histological grading,residual lesions,ascites,preoperative HE4,postoperative CA125 and lymph node resection.Independent risk factors for recurrence of epithelial ovarian cancer patients with initial cytoreductive surgery were analyzed.Results:There were 78 cases of recurrent disease,the recurrence rate was 41.94%,and 108 cases were not recurrence in the postoperative 5 years follow-up.There was no significant difference in age,histological type,chemotherapy,neoadjuvant chemotherapy and other factors between the recurrent group and the non recurrence group (P＞0.05),but the clinical staging,histological grading,residual lesions,ascites,preoperative HE4,postoperative CA125 and lymph node resection between the two groups showed a significant difference (P＜0.05).Logistic regression analysis showed that clinical staging,residual lesions,ascites,preoperative HE4 and lymph node dissection were the independent risk factors of recurrence after initial cytoreductive surgery in patients with epithelial ovarian cancer ［OR=9.786(3.484~27.493,OR=8.199(4.431~15.172),OR=9.143(3.975~21.031),OR=9.337(4.593~18.983),OR=11.917(6.440~22.053)］.Conclusion:According to the results of this study,the recurrence rate of epithelial ovarian cancer patients after initial cytoreductive surgery was about 41.94%,and the independent risk factors of postoperative recurrence were clinical stage,residual lesions,ascites,preoperative HE4,Lymph node resection.Clinical intervention can be carried out according to these factors to reduce the recurrence rate and improve the quality of life.

References:

［1］Zhang SS,Xia QM,Zheng RS,et al.Analysis of incidence and mortality of ovarian cancer in China in 2010［J］.中国肿瘤,2016,25(3):169-173.［张爽爽,夏庆民,郑荣寿,等.中国2010年卵巢癌发病与死亡分析［J］.中国肿瘤,2016,25(3):169-173.］
［2］Li C,Wu YM.Research progress in ovarian cancer and related molecular metastasis mechanisms［J］.Journal of Oncology,2015,21(1):61-65.［李晨,吴玉梅.卵巢癌与相关分子转移机制的研究进展［J］.肿瘤学杂志,2015,21(1):61-65.］
［3］Li XQ,Wang XY.Advances in precision treatment of epithelial ovarian cancer ［J］.Chinese Journal of Practical Gynecology and Obstetrics,2016,32(8):810-813.［李秀琴,王欣彦.上皮性卵巢癌精准治疗研究进展［J］.中国实用妇科与产科杂志,2016,32(8):810-813.］
［4］Tian H,Yu P,Wu XM,et al.Research progress in therapeutic drugs for ovarian cancer［J］.Modern Medicine & Clinical Medicine,2015,36(1):103-107.［田红,于鹏,吴小茗,等.卵巢癌的治疗药物研究进展［J］.现代药物与临床,2015,36(1):103-107.］
［5］Bian C.Neoadjuvant chemotherapy in the treatment of advanced ovarian cancer［J］.Journal of Practical Obstetrics and Gynecology,2015,31(4):263-266.［边策.新辅助化疗在晚期卵巢癌治疗中的应用［J］.实用妇产科杂志,2015,31(4):263-266.］
［6］Hu Y.Analysis of related factors of ovarian cancer ［J］.Maternal and Child Health Care of China,2015,30(29):5040-5041.［胡玥.卵巢癌发生的相关因素分析［J］.中国妇幼保健,2015,30(29):5040-5041.］
［7］Jia SJ,Wang ZJ,Zhang MQ,et al.The value of serum CA125,HE4 and imaging in the diagnosis of postoperative recurrence of epithelial ovarian cancer［J］.Chinese Journal of Cancer,2015,25(6):452-456.［贾素娟,王治洁,张美琴,等.血清CA125、HE4和影像学检查在上皮性卵巢癌术后复发诊断中的应用价值［J］.中国癌症杂志,2015,25(6):452-456.］
［8］Liu YN,Gao AH,Zhu WP.The expression of ASAP1 protein in epithelial ovarian cancer and its clinical significance［J］.Journal of Jiangsu University(Medical Sciences),2015,25(6):495-497.［刘亚南,高爱华,朱维培.上皮性卵巢癌组织中ASAP1蛋白的表达及其临床意义［J］.江苏大学学报(医学版),2015,25(6):495-497.］
［9］Huang ZY,Ma BD,Huang ZM.Tumor-free survival and its influencing factors in women with recurrent epithelial ovarian cancer［J］.Chinese Journal of Maternal and Child Health Research,2017,28(7):526-527.［黄志有,马必东,黄兆明.复发性卵巢上皮癌女性患者无瘤生存状况及其影响因素分析［J］.中国妇幼健康研究,2017,28(7):526-527.］
［10］Sun XX,Li J,Li N,et al.Expression and clinical significance of EGR4 in epithelial ovarian cancer［J］.Modern Oncology Medicine,2017,25(18):2963-2967.［孙小霞,李佳,李娜,等.EGR4在上皮性卵巢癌组织中的表达及其临床意义［J］.现代肿瘤医学,2017,25(18):2963-2967.］
［11］Zhang J,Wang XH,Zhang M,et al.56 cases of recurrent ovarian cancer disease-free survival factors and prognosis analysis after treatment ［J］.Journal of Practical Obstetrics and Gynecology,2016,32(5):354-357.［张洁,王晓慧,张苗,等.56例复发性卵巢癌无瘤生存期影响因素及治疗后预后分析［J］.实用妇产科杂志,2016,32(5):354-357.］
［12］Gong YY,Hu YJ.Analysis of relevant influencing factors of clinical recurrence of ovarian epithelial carcinoma at stage II and above ［J］.Modern Advances in Obstetrics and Gynecology,2017,26(3):207-209.［宫迎迎,胡元晶.Ⅱ期及以上卵巢上皮性癌临床复发的相关影响因素分析［J］.现代妇产科进展,2017,26(3):207-209.］
［13］Thomakos N,Biliatis I,Koutroumpa I,et al.Prognostic factors for recurrence in early stage adult granulosa cell tumor of the ovary［J］.Archives of Gynecology & Obstetrics,2016,294(5):1-6.
［14］Ye JL,Gao Y.Analysis of factors affecting the recurrence of epithelial ovarian cancer［J］.Anhui Medicine,2015,43(2):167-170.［叶俊良,高杨.上皮性卵巢癌复发的影响因素分析［J］.安徽医学,2015,43(2):167-170.］
［15］Heitz F,Harter P,Alesina PF,et al.Pattern of and reason for postoperative residual disease in patients with advanced ovarian cancer following upfront radical debulking surgery［J］.Gynecologic Oncology,2016,141(2):264.
［16］Wang SH,Yang T.Observation and nursing of postoperative complications of ovarian cancer cells reduction and excision［J］.Beijing Medical Journal,2015,51(4):396-397.［王胜花,杨婷.卵巢癌细胞减灭术后并发症的观察及护理［J］.北京医学,2015,51(4):396-397.］
［17］Jin M,Zhang Y,Wu X.Clinical pathological factors affecting the prognosis of patients with recurrent epithelial ovarian cancer［J］.Maternal and Child Health Care of China,2017,32(13):2897-2899.［金敏,张羽,吴霞.影响复发上皮性卵巢癌患者预后的临床病理因素分析［J］.中国妇幼保健,2017,32(13):2897-2899.］
［18］Yan H,He Y,Yang RF,et al.Clinical characteristics of recurrent ovarian cancer ［J］.Chinese Med J Peking 2015,17(4):487-490.［严浩,何杨,杨润峰,等.复发性卵巢癌的临床特点分析［J］.中国医师杂志,2015,17(4):487-490.］

Memo

Memo:
-
Last Update: 1900-01-01